Impax Laboratories, Inc. - News - Press Releases

Home

About Impax

Corporate Responsibility

Corporate Responsibility

Products

Research

Investor Relations

News

Press Releases

Careers

Benefits of Joining Our Team

Contact

2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Nov 25, 2015

Impax Receives European Commission Marketing Authorization for NUMIENT™ (Levodopa and Carbidopa) Modified-Release Capsules for the Symptomatic Treatment of Adult Patients with Parkinson's Disease

Nov 24, 2015

Impax Launches Generic Version of Avodart® (Dutasteride) Capsules, 0.5 mg

Nov 09, 2015

Impax Reports Third Quarter 2015 Financial Results

Nov 05, 2015

Impax to Present at the 24th Annual Credit Suisse Healthcare Conference

Oct 21, 2015

Impax Receives FDA Approval for Generic Version of Intuniv® (Guanfacine) Extended-Release Tablets, 1 mg, 2 mg, 3 mg and 4 mg

Oct 09, 2015

Impax to Report Third Quarter 2015 Results on November 9, 2015

Oct 08, 2015

Janet S. Vergis Appointed to Impax Laboratories Board of Directors

Oct 05, 2015

Impax Receives FDA Approval for Generic Version of DIABETA® (Glyburide) Tablets, USP, 1.25 mg, 2.5 mg, and 5 mg

Sep 25, 2015

Impax Receives Positive CHMP Opinion for NUMIENT™ (Levodopa and Carbidopa) Modified-Release Capsules for the Symptomatic Treatment of Adult Patients with Parkinson's disease

Sep 22, 2015

Impax Receives FDA Approval for Generic Version of Testred® C-III (Methyltestosterone Capsules, USP), 10 mg

Sep 17, 2015

Impax Receives FDA Approval for Generic Version of Mestinon® Timespan® Tablets, 180 mg

Sep 11, 2015

Impax to Present at the Morgan Stanley Global Healthcare Conference

Sep 08, 2015

Impax Announces Resolution of FDA Warning Letter Related to its Hayward Manufacturing Facility

Aug 10, 2015

Impax Announces Sale of Daraprim® to Turing Pharmaceuticals AG

Aug 10, 2015

Impax Reports Second Quarter 2015 Financial Results

Jul 06, 2015

Impax to Report Second Quarter 2015 Results on August 10, 2015

Jul 06, 2015

Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors

Jun 25, 2015

Impax Laboratories, Inc. Prices Private Offering of Convertible Senior Notes

Jun 24, 2015

Impax Laboratories, Inc. Announces Private Offering of Convertible Senior Notes

Jun 16, 2015

FDA Approves ZOMIG® (zolmitriptan) Nasal Spray for Migraine in Pediatric Patients (Ages 12-17)

Jun 04, 2015

Impax to Present at the Goldman Sachs 36th Annual Global Healthcare Conference

May 14, 2015

Impax to Present at the UBS 2015 Global Healthcare Conference

May 11, 2015

FDA Performs GMP and Pre-Approval Inspections of Impax's Hayward Facility

May 11, 2015

Impax Reports First Quarter 2015 Financial Results

May 08, 2015

Impax to Present at the Bank of America Merrill Lynch 2015 Health Care Conference

May 04, 2015

Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance

Apr 16, 2015

Impax to Report First Quarter 2015 Results on May 11, 2015

Mar 10, 2015

Impax Completes Acquisition Of Tower Holdings, Inc. And Lineage Therapeutics Inc.

Feb 25, 2015

Impax to Present at the Cowen and Company 35th Annual Health Care Conference

Feb 24, 2015

Impax Revenues Increased 30% to $131 Million in Fourth Quarter 2014

Jan 29, 2015

Impax to Report Fourth Quarter 2014 Results on February 24, 2015

Jan 26, 2015

Impax Receives FDA Approval for a Generic Version of Lamictal® Orally Disintegrating Tablets (ODT)

Jan 08, 2015

Impax Pharmaceuticals Announce FDA Approval of RYTARY™ (Carbidopa and Levodopa) Extended-Release Capsules for the Treatment of Parkinson's disease

Jan 06, 2015

Impax to Present at the 33rd Annual J.P. Morgan Healthcare Conference

© Impax Laboratories, LLC

Powered By Q4 Inc. 5.14.0.5